Secondary outcome measures obtained by clinical examination at 1 and 26 weeks*
| 1 Week PRP (n=41) | Placebo (n=39) | Adjusted between-group difference† (95% CI) | 26 weeks PRP (n=41) | Placebo (n=39) | Adjusted between-group difference† (95% CI) | |
|---|---|---|---|---|---|---|
| Active knee extension deficit, degrees | 3±10 | 7±9 | −4 (−7 to −1)‡ | −1±5 | 1±5 | −2 (−5 to 1) |
| Passive straight leg raise deficit, degrees | 2±5 | 2±3 | 0 (−2 to 3) | −2±6 | 0±6 | −1 (−3 to 1) |
| Isometric knee flexion strength testing | ||||||
| Strength deficit in 15° knee flexion, % | 13±21 | 13±20 | −1 (−10 to 7) | −1±18 | 1±14 | −2 (−11 to 6) |
| Strength deficit in 90° knee flexion, % | 11±17 | 7±18 | 2 (−5 to 9) | 3±14 | 1±13 | 2 (−5 to 9) |
| Pain score in 15° knee flexion | 1.6±1.9 | 1.7±2.2 | −0.1 (−0.8 to 0.7) | 0.4±1.3 | 0.5±1.6 | −0.1 (−0.9 to 0.7) |
| Pain score in 90° knee flexion | 1.3±1.7 | 1.9±2.3 | −0.6 (−1.3 to 0.2) | 0.4±1.3 | 0.5±1.6 | 0.1 (−0.7 to 0.9) |
*Plus–minus values are means±SD.
†Between-group differences are adjusted for the baseline measure.
‡Statistical significant difference (p=0.01).
PRP, platelet-rich plasma.